Centene Earnings Call: Big EPS Beat, Cautious Outlook

Centene ((CNC)) has held its Q1 earnings call. Read on for the main highlights of the call.

Centene’s latest earnings call struck a cautiously upbeat tone, as management highlighted a sizable first‑quarter earnings beat, stronger‑than‑planned Medicare results and improving Medicaid margins. At the same time, executives underscored persistent medical and pharmacy cost pressures, Marketplace utilization issues and an earnings profile heavily skewed to the first quarter, arguing for continued conservatism in guidance.

EPS Beat Sparks Confident Upgrade to 2026 Outlook

Centene opened the call with a standout earnings surprise, delivering adjusted diluted EPS of $3.37 for the first quarter of 2026, roughly $0.50 above consensus expectations. On the back of this performance, the company raised its full‑year adjusted EPS outlook to greater than $3.40, up from prior guidance of more than $3.00, while stressing that assumptions remain deliberately cautious.

Revenue Scale and Cash Generation Underpin Financial Flexibility

The company reported first‑quarter premium and service revenue of $44.7 billion, underscoring its position as one of the largest players in U.S. government‑sponsored health care. Cash flow provided by operations reached $4.4 billion in Q1, leaving $437 million of cash available for general corporate purposes and enhancing its ability to navigate volatility and pursue capital deployment options.

Medicaid Margins Strengthen as Rate and Trend Stay in Balance

Medicaid performance was a clear bright spot, with the segment health benefits ratio improving to 93.1% in Q1 2026, a 50‑basis‑point gain versus the prior‑year quarter. Medicaid membership ended the period at 12.4 million, and management expects a composite rate yield of roughly 4.5% against net trend in the mid‑4% range, signaling a relatively healthy rate‑trend balance.

Medicare Segment Outperforms With PDP Scale and MA Path

Centene’s Medicare book delivered better‑than‑forecast results, with a segment HBR of 84.9% as both Medicare Advantage and Part D plans contributed. PDP membership finished the quarter at just over 8.7 million, and leadership reiterated progress on a path to breakeven for Medicare Advantage by 2027, framing the business as a future earnings contributor rather than a drag.

Marketplace Membership Grows as Data Visibility Improves

On the Marketplace side, Ambetter membership ended Q1 at approximately 3.58 million, with management emphasizing the value of its collaboration with peers and the analytics firm Wakely. Earlier access to market demographics and risk signals has reinforced Centene’s view that its Silver tier cohort is higher acuity and should generate a meaningful risk adjustment receivable over time.

SG&A Discipline Supports Margins and Earnings Power

The company continued to tighten its expense base, with the consolidated adjusted SG&A ratio improving to 7.6% in Q1 from 7.9% a year earlier, a 30‑basis‑point reduction. Reflecting that progress, Centene lowered its full‑year consolidated SG&A guidance by a further 10 basis points and added $50 million to expected investment income, bolstering confidence in operating leverage.

Liability Management and Balance Sheet Strengthen

Centene executed on balance sheet optimization by selling $1.0 billion of 2025 Part D receivables and using the proceeds to repurchase $1.0 billion of senior notes. As a result, the debt‑to‑capital ratio improved to 43.2% from 46.5% at year‑end, while medical claims liability stood at $20.6 billion, equal to 48 days in claims payable and reflecting modest working capital timing pressure.

Operational Initiatives and Leadership Evolution Gain Traction

Management spotlighted scaled trend‑management initiatives, including utilization management, network optimization, clinical programs and payment integrity, noting that these efforts are already showing constructive early results. The company also advanced its leadership evolution by elevating Dan Finke and Michael Carson to Group President roles and highlighted a top‑50 ranking on Forbes’ Best Employers for company culture as evidence of organizational momentum.

Silver Tier Utilization Weighs on Marketplace Margins

Despite overall membership growth, Marketplace profitability came under pressure in Q1 as the HBR ran slightly higher than expected, driven by elevated utilization concentrated in Silver tier members. In response, management embedded only a partial risk adjustment receivable into guidance and cut the assumed Marketplace pretax margin to about 3% from roughly 4%, effectively trimming embedded profitability by around 100 basis points.

Persistent Medical and Pharmacy Trend Risks Remain a Watch‑Item

Executives reiterated that historically elevated medical and pharmacy cost trends remain a core risk across the portfolio, particularly in behavioral health, home health and high‑cost specialty drugs. While internal programs are aimed at mitigating these pressures, management was clear that trends remain above pre‑2024 baselines and will stay a key driver of medical costs for the foreseeable future.

Part D Specialty Pressures and 2027 Model Mismatch Loom

Within the Part D pharmacy business, specialty trend in the non‑LIS PDP population remains very high, even after some moderation versus earlier assumptions. Management cautioned that for 2027 the risk model will not reflect recent legislative changes, which could materially increase the direct subsidy and push costs higher, adding another source of medium‑term earnings uncertainty.

Seasonal Earnings Profile Points to Choppy Quarters Ahead

Centene reaffirmed that earnings will be heavily front‑loaded this year, with Q1 representing the peak quarter. The company expects a step down in EPS from Q1 to Q2, albeit still profitable, a roughly breakeven third quarter and a loss in Q4 driven in part by heavier SG&A spending, implying investors should prepare for an uneven quarterly cadence.

Marketplace Outlook Hinges on June Wakely Data

The company emphasized that several key Marketplace assumptions are tied to forthcoming June Wakely risk and claims data, which will help refine estimates for the ultimate risk adjustment receivable. Current guidance intentionally does not reflect the full potential benefit from that offset, leaving a degree of near‑term uncertainty but also possible upside if the data corroborate management’s expectations.

Refinancing and Claims Payable Trends Add to Risk List

Centene acknowledged future balance sheet considerations, noting upcoming debt maturities of roughly $1.2 billion in 2027 and about $2.3 billion in 2028 that are likely to be refinanced, creating exposure to the prevailing interest rate environment. At the same time, days in claims payable increased to 48 days, up two days from the fourth quarter of 2025, signaling modest timing‑related pressure in working capital.

Program Integrity and Regulatory Uncertainty Cloud Longer‑Term View

Management also flagged legal and regulatory uncertainty around certain program integrity initiatives implemented in 2025 that have been stayed pending court outcomes. These decisions could affect Marketplace membership completeness and how program integrity measures flow through into 2027, adding another layer of policy‑related risk that investors will need to monitor.

Guidance: Higher EPS Target, but With Built‑In Caution

For the full year, Centene now targets adjusted EPS of greater than $3.40, underpinned by $44.7 billion of Q1 premium and service revenue, a consolidated Q1 HBR of 87.3% and stable full‑year HBR guidance of 90.9%–91.7%. The outlook assumes Medicaid net trend in the mid‑4% range with a roughly 4.5% composite rate yield, year‑end Medicaid membership down about 6% year over year, a consolidated SG&A ratio nudged lower and only a 3% Marketplace pretax margin with limited assumed risk adjustment benefit until June data arrive.

Centene’s earnings call painted a picture of a company executing well on its core government programs, using scale, SG&A discipline and liability management to support earnings even as medical and pharmacy trends run hot. With EPS guidance raised yet still framed conservatively, investors are left weighing tangible operational progress and balance sheet improvements against persistent cost, regulatory and seasonality risks that could drive volatility through the rest of the year.